Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (846)	11/5/2003 8:17:29 PM
From: tuck	Read Replies (2) \| Respond to of 1005

Another one crawls out the window: >>NEW YORK, Nov 5 (Reuters) - Drug firm Pharmion Corp., which focuses on the treatment of hematology and oncology patients, priced its initial public offering of 6 million shares at $14 share on Wednesday. The Boulder, Colorado-based company hopes to use the proceeds to expand its sales and marketing organization and to acquire or license additional late-stage approved products. The underwriters, led by Morgan Stanley and J.P. Morgan, will be granted the option to buy 900,000 more shares in case of heavy demand for the IPO shares. Pharmion, which has applied for a Nasdaq listing under the symbol "PHRM" (Nasdaq:PHRM - News), has two products, Thalidomide Pharmion and Vidaza, in advanced stages of development. They were obtained through licensing arrangements with companies including Celgene Corp. (NasdaqNM:CELG - News) and Schering AG (XETRA:SCHG.DE - News), among others. It has acquired the rights to two marketed products, Innohep to treat blood clots in the deep veins of the legs, and Refludan for heparin-induced thrombocytopenia, an allergic response resulting in an absence of enough cell platelets to enable blood clotting.<< Cheers, Tuck

To: Jibacoa who wrote (846)	11/13/2003 4:37:24 PM
From: tuck	Read Replies (1) \| Respond to of 1005

I don't know what's juicing LSBC's ride; I concluded they were headed for a slow death spiral. BLUE HP was hoping for a some folks to overreact to a few minor contract wins, but so far, investors' responses to those have been properly measured. The recent strength is something of a mystery. New president and perhaps an ally at Dow? BLUE HP watching more closely now, trying to decide if it can break even on that sucker. Meanwhile, INGN scores another important IP win over SGP: >>AUSTIN, Texas, Nov. 13 /PRNewswire-FirstCall/ -- Introgen Therapeutics (Nasdaq: INGN - News) announced today that its exclusively licensed European Patent 0 760 675, directed to combination therapy with p53 and standard chemotherapy or radiotherapy, was upheld by the European Patent Office as amended following an opposition brought by Schering-Plough Corporation (NYSE: SGP - News). The patent, exclusively licensed to Introgen from The Board of Regents of The University of Texas System, is one of the cornerstones of Introgen's formidable patent estate covering its Advexin® Ad-p53 product candidate. This is the third successful outcome over a period of three years in oppositions involving Schering-Plough. Dr. David L. Parker, Introgen's vice president for intellectual property said, "This is a very important win for Introgen on the European patent front. This patent is strategically important in that it covers the administration of p53, in any form, after the administration of virtually any type of conventional chemotherapy or radiotherapy. We are gratified to report that it has withstood the initial opposition and is a significant patent in our estate." Introgen controls twenty-six issued patents and has a large number of pending United States and international applications that relate to its p53 technologies. Covered under the issued patents is the clinical use of adenoviral p53 in the treatment of cancer, as well as the use of p53 gene therapy in combination with conventional chemotherapy and radiation, regardless of the gene delivery system used. Introgen also owns an issued patent related to processes for the commercial scale production of adenoviruses. Dr. Parker added, "This European patent compliments Introgen's multifaceted patent estate, which includes numerous patents on adenoviral p53, clinical therapy with adenoviral p53, combination p53 therapy with taxanes such as Taxotere® or Taxol®, and combination p53 therapy with other classes of chemotherapy drugs called DNA repair inhibitors."<< snip I own no BLUE HP stocks now, but my Mom owns AMEV, TELK, CALP, GNVC, & INGN. I'm pleased to report she is comfortably ahead on all except CALP (slightly underwater). LSBC, however didn't work so well. In aggregate, though, she's ahead on these stocks. Cheers, Tuck